Australian authorities have launched an investigation after a recipient of the AstraZeneca COVID-19 vaccine developed blood clots.
The 44-year-old Melbourne man was admitted to a hospital just lately with a clotting dysfunction after receiving the vaccine on March 22.
Michael Kidd, Australia’s appearing chief medical officer, stated on Saturday that “it’s seemingly” the person’s situation is expounded to the vaccine.
“Whereas presently, we do not have proof of causality, the medical options of this case are in keeping with what we’ve got seen in worldwide reviews of comparable circumstances. And it’s seemingly that the case reported yesterday is expounded to the vaccine,” he advised reporters in Canberra.
The Australian Technical Advisory Group on Immunization (ATAGI) stated in an announcement on Friday that they have been at the moment investigating this case and dealing with worldwide specialists and regulators to supply recommendation on the optimum use of the AstraZeneca vaccine.
“We’ve got issued communication for shoppers and clinicians on the importance of this situation and to be alert for the signs and indicators of thromboses,” stated the assertion.
“ATAGI has not modified its recommendation on using the AstraZeneca vaccine presently.”
The European Medicines Company performed a evaluation of the protection and efficacy of the vaccine in March, discovering a “doable hyperlink” between it and blood clots however ruling that the advantages “outweigh the chance.”
Australia has agreed to amass 53.8 million doses of the vaccine, most of which will probably be manufactured domestically by biotechnology firm CSL.